Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer

NCT01301729 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01301729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01301729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2011
Completion date
July 31, 2014
Enrollment
32 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer